Presentation
17 March 2023 Photodynamic therapy for basal cell carcinoma is enhanced by pretreatment with oral vitamin D: interim results of a clinical trial
Author Affiliations +
Abstract
Photodynamic therapy with aminolevulinic acid and blue light is used in Europe for basal cell carcinoma (BCC), but not in the United States due to uncertainties about efficacy. To potentially improve treatment outcomes and make PDT a more attractive as therapy for BCC, we conducted a prospective, double-blind, crossover clinical trial to test whether pretreatment with oral Vitamin D may enhance BCC responses to blue light PDT. Three separate PDT sessions were administered, with patients receiving daily doses of Vitamin D (10,000 units) or placebo for a week prior to PDT. We will report here on interim clinical trial outcomes.
Conference Presentation
© (2023) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Edward V. Maytin, Lauren Heusinkveld, Jeffrey Negrey, Abigail Updyke, Sanjay Anand, Christine B. Warren, Nathalie Zeitouni, and Tayyaba Hasan "Photodynamic therapy for basal cell carcinoma is enhanced by pretreatment with oral vitamin D: interim results of a clinical trial", Proc. SPIE PC12359, Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy XXXI, PC123590B (17 March 2023); https://doi.org/10.1117/12.2651169
Advertisement
Advertisement
KEYWORDS
Photodynamic therapy

Clinical trials

Tumors

Digital cameras

Skin cancer

Tumor growth modeling

Back to Top